Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Therakos LLC
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07619898CT.gov PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure | — | Not Yet Recruiting | — | — | — |
NCT06646016CT.gov EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| VITPSO (this asset) | Therakos LLC | P2 | CCC · 53 |
| Infliximab | Therakos LLC | P2 | B |
| Vedolizumab | Therakos LLC | P2 | B |
| Tacrolimus | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Azathioprine | Therakos LLC | P2 | CCC |
| Adalimumab | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Mesalamine | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Mercaptopurine Anhydrous | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Docosahexaenoic Acid | Beth Israel Deaconess Medical Center | P1 | CC |
+3 more in the Colitis cohort
Other indications for VITPSO
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mycosis Fungoides | — | P4 | BB · 67 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 67 |
| Acquired Epidermolysis Bullosa | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. VITPSO in Colitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vitpso-colitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →